The Pulse Check

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Apr 7, 2026

•

21 min read

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Jason Segal

The Pulse Check

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Mar 31, 2026

•

18 min read

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Jason Segal

The Pulse Check

Mar 30, 2026

•

9 min read

Why Peptides Are Suddenly Everywhere

Jason Segal

Lumos Diagnostics (ASX: LDX)

Crowned then Clipped: When the Raise Gets There Before the Rally

Mar 27, 2026

•

6 min read

Crowned then Clipped: When the Raise Gets There Before the Rally

Jason Segal

Lumos Diagnostics (ASX: LDX)

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Mar 26, 2026

•

9 min read

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Jason Segal

The Pulse Check

Mar 25, 2026

•

5 min read

Why Iran Matters for Biotech Investors

Jason Segal

The Pulse Check

What makes a surgeon use a product? The Orthocell (ASX: OCC) Story.

Mar 24, 2026

•

17 min read

What makes a surgeon use a product? The Orthocell (ASX: OCC) Story.

Jason Segal

Amplia (ASX: ATX)

Mar 23, 2026

•

7 min read

Amplia (ASX: ATX) Delivers: A Result the Biotech Sector Needed

Jason Segal

Amplia (ASX: ATX)

Mar 20, 2026

•

10 min read

Amplia (ASX: ATX) in the Spotlight: Bull, Bear, Base

Jason Segal

The Pulse Check

Don’t sleep on this one: The Avecho (ASX: AVE) Story

Mar 19, 2026

•

15 min read

Don’t sleep on this one: The Avecho (ASX: AVE) Story

Jason Segal

The Pulse Check

Mar 18, 2026

•

3 min read

Flash update on my day trip to Brisbane

Jason Segal

The Pulse Check

Medical Device Playbook: From FDA Clearance to Commercial Success

Mar 17, 2026

•

16 min read

Medical Device Playbook: From FDA Clearance to Commercial Success

Jason Segal

The Pulse Check

First pick flying, plus my plans for the Armchair Portfolio

Mar 16, 2026

•

7 min read

First pick flying, plus my plans for the Armchair Portfolio

Jason Segal

The Pulse Check

My First Armchair Pick: Tetratherix (ASX: TTX)

Mar 16, 2026

•

24 min read

My First Armchair Pick: Tetratherix (ASX: TTX)

Jason Segal

The Pulse Check

Mar 13, 2026

•

4 min read

The Curse of the Friday the 13th

Jason Segal

The Pulse Check

Mar 12, 2026

•

5 min read

A Nervous Wait for the Immutep Results

Jason Segal

The Pulse Check

Boom or Bust: The Immutep (ASX: IMM) Trade

Mar 11, 2026

•

10 min read

Boom or Bust: The Immutep (ASX: IMM) Trade

Jason Segal

The Pulse Check

Bloodbath Yesterday. Bounce Today? The Market Seasaw

Mar 10, 2026

•

9 min read

Bloodbath Yesterday. Bounce Today? The Market Seasaw

Jason Segal

The Pulse Check

Trust Your Gut: The Microba (ASX: MAP) Story

Mar 6, 2026

•

13 min read

Trust Your Gut: The Microba (ASX: MAP) Story

Jason Segal

The Pulse Check

The M&A Slide Just Updated Itself: $1.5 billion deal

Mar 5, 2026

•

5 min read

The M&A Slide Just Updated Itself: $1.5 billion deal

Jason Segal

The Pulse Check

Three Shots, One Strategy: The Syntara (ASX: SNT) Story

Mar 4, 2026

•

12 min read

Three Shots, One Strategy: The Syntara (ASX: SNT) Story

Jason Segal

The Pulse Check

Risk On, Risk Off: Understanding the Market’s Rhythm

Mar 2, 2026

•

6 min read

Risk On, Risk Off: Understanding the Market’s Rhythm

Jason Segal

The Pulse Check

A US-First Strategy for Ovarian Cancer Screening: The Cleo (ASX: COV) story

Feb 27, 2026

•

14 min read

A US-First Strategy for Ovarian Cancer Screening: The Cleo (ASX: COV) story

Jason Segal

The Pulse Check

Feb 26, 2026

•

7 min read

Half-Yearlys are out. Score Check?

Jason Segal

The Pulse Check

Climbing the Diagnostics Mount Everest: The BCAL (ASX: BDX) Story

Feb 25, 2026

•

17 min read

Climbing the Diagnostics Mount Everest: The BCAL (ASX: BDX) Story

Jason Segal

The Pulse Check

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Why Peptides Are Suddenly Everywhere

Crowned then Clipped: When the Raise Gets There Before the Rally

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Why Iran Matters for Biotech Investors

What makes a surgeon use a product? The Orthocell (ASX: OCC) Story.

Amplia (ASX: ATX) Delivers: A Result the Biotech Sector Needed

Amplia (ASX: ATX) in the Spotlight: Bull, Bear, Base

Don’t sleep on this one: The Avecho (ASX: AVE) Story

Flash update on my day trip to Brisbane

Medical Device Playbook: From FDA Clearance to Commercial Success

First pick flying, plus my plans for the Armchair Portfolio

My First Armchair Pick: Tetratherix (ASX: TTX)

The Curse of the Friday the 13th

A Nervous Wait for the Immutep Results

Boom or Bust: The Immutep (ASX: IMM) Trade

Bloodbath Yesterday. Bounce Today? The Market Seasaw

Trust Your Gut: The Microba (ASX: MAP) Story

The M&A Slide Just Updated Itself: $1.5 billion deal

Three Shots, One Strategy: The Syntara (ASX: SNT) Story

Risk On, Risk Off: Understanding the Market’s Rhythm

A US-First Strategy for Ovarian Cancer Screening: The Cleo (ASX: COV) story

Half-Yearlys are out. Score Check?

Climbing the Diagnostics Mount Everest: The BCAL (ASX: BDX) Story

The Armchair Analyst